CD274 and cancer: Since the first discovery of PD‐1/PD‐L1 axis two decades ago as a negative regulator of T cell activity, PD‐1/PD‐L1 blocking antibodies and related combination therapies have achieved remarkable success in cancer patients[6, 7] (Figure 1).